Advanced Enzyme Technologies Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 369.75 as of 12 May 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 210.71 crore as compare to the Dec '25 revenue of ₹ 191.66 crore. This represent the growth of 9.94% The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the decline of -100% The ebitda of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 70.57 crore as compare to the Dec '25 ebitda of ₹ 69.07 crore. This represent the growth of 2.17% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -100% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 45.25 crore over 8 quarters. This represents a CAGR of 13.74% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 4,370 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 66,321 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd?

As of May 12, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹390.3. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2350.15.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.